These injections are carefully tailored to address individual needs and administered under medical supervision
McLean BA, Wong CK, Kaur KD, et al
The FDA is not aware of any basis for compounding a drug using semaglutide salts that would meet the requirements of the federal Food, Drug, and Cosmetic (FD&C) Act. Salt forms have not been shown to be safe and effective. The FDA has received adverse event reports after patients used compounded semaglutide
The neuroprotective effects of both BPC-157 and TB-500 are particularly relevant here, as L5 nerve compression can cause foot drop if not addressed
IV infusions cost more per session but address multiple deficiencies simultaneously, which can reduce the total number of appointments needed
The injectable form has high bioavailability, while oral semaglutide (Rybelsus) uses the SNAC absorption enhancer and has only ~1% oral bioavailability, requiring strict fasting conditions